<p>Fudan-Zhangjiang (01349.HK) issued a profit warning, expecting a net loss of between RMB 120 million and RMB 180 million for the fiscal year 2025, compared to a net profit of RMB 39.73 million in the previous year. The reason is that the group is actively promoting the progress of R&amp;D projects, with R&amp;D investment as a proportion of operating income continuously increasing; the product Libo Duo has not been selected for the national procurement catalog, and the company has adjusted its sales strategy to lower market retail prices, resulting in a reduction of approximately RMB 100 million in profit contribution from the products</p>

159316

159837

688505

<p>Fudan-Zhangjiang issued a profit warning, expecting a net loss of between 120 million and 180 million RMB for the fiscal year 2025, compared to a net profit of 39.73 million RMB in the previous year. The reason is that the group is actively promoting the progress of research and development projects, with R&D investment as a proportion of operating income continuously increasing; the product Libo Duo has not been selected for the national procurement catalog, and the company has accordingly adjusted its sales strategy to lower market retail prices, resulting in a reduction of approximately 100 million RMB in profit contribution from the products</p>

AASTOCKS

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI Biotechnology Theme ETF

Fudan-Zhangjiang

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

FUDANZHANGJIANG

Guotai CSI Bio-medicine ETF

"Profit Warning" Fudan-Zhangjiang estimates a full-year loss of 120 million to 180 million RMB